Skip to main content
. 2022 Apr 15;22:143. doi: 10.1186/s12883-022-02656-8

Fig. 2.

Fig. 2

Frequency of MS relapses during 48 months of treatment with fingolimod. Data presented as percentage of patients (Wald 95% CI) CI, confidence interval; MS, multiple sclerosis; N’, total number of patients with relapses; n, number of patients with the individual outcomes